About this Research Topic
Malignant liver tumors include a wide range of primary and secondary tumors. Primary liver cancer is one of the most common malignancies worldwide. According to the 2018 Global Cancer Statistics, it ranks 7th and 3rd among all cancers in terms of global incidence and mortality, respectively.
Primary liver tumors include Hepatocellular carcinoma (85%), Cholangiocarcinoma (10-12%), and sarcoma which account for about 6% of the total cancer burden worldwide. With regards to secondary tumors, the most frequent are colorectal and breast cancer. Surgery is the standard treatment for primary and secondary liver tumors, offering the best long-term outcome in term of survival. The benefit of surgery in term of disease free survival is under debate, however, mostly due to the high rate of recurrence after surgical treatment. Repeat resection for hepatic recurrence appears safe and feasible but further studies need to support this trend. Resection range can vary depending on tumor location, size, liver function and future remnant liver, covering only hepatic parenchyma around the tumor (parenchyma sparing), to extensive hepatectomy and vascolar reconstruction or ex-situ liver resection. Due to improvements in surgical outcomes as well as the efficacy of systemic treatments the role of surgery has changed in recent years and it has became more aggressive.
This Research Topic welcomes submissions related to recurrence of liver tumors, with a particular focus on surgical treatment options including parenchyma sparring, mini-invasive surgery, and multimodal therapies.
Keywords: liver tumors, parenchyma sparing, mininvasive surgery, recurrence disease, multimodal therapies
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.